

Supplementary

Anti-IL-6 Receptor Treatment in Giant Cell Arteritis Patients Reduces Levels of IL-1 β -Receptor Antagonist but Not IL-1 β

Joana J. da Costa ^{1,2,3}, Lisa Christ ⁴, Peter M. Villiger ⁵, Monique Vogel ^{1,2} and Martin F. Bachmann ^{1,2,6*}

¹ Department of Immunology, University Clinic for Rheumatology and Immunology, University of Bern, 3012 Bern, Switzerland; joana.jorgedacosta@dbmr.unibe.ch (J.J.d.C.); monique.voguel@unibe.ch (M.V.)

² Department of Biomedical Research Bern (DBMR), University of Bern, 3012 Bern, Switzerland

³ Graduate School for Cellular and Biomedical Sciences (GCB), University of Bern, 3012 Bern, Switzerland

⁴ Department of Rheumatology and Immunology, Inselspital, Bern University Hospital, University of Bern, 3012 Bern, Switzerland; lisa.christ@insel.ch

⁵ Medical Center Monbijou, 3011 Bern, Switzerland; peter.villiger@hin.ch

⁶ Nuffield Department of Medicine, The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK;

* Correspondence: martin.bachmann@unibe.ch

Table S1: Immunological markers studied from phase II RCT

undetectable Biomarkers (N=18) Biomarkers with non-significant		undetectable Biomarkers (N=18) Biomarkers with non-significant		undetectable Biomarkers (N=18) Biomarkers with non-significant
IL-2	IL-34	APRIL/TNFSF13	MMP-2	Pentraxin-3
IL-10	IL-32	BAFF/TNFSF13B	ICAM-1	MMP-3
L-11	IL-29/IFN- λ 1	sCD30/TNFSF8	hsCRP	sCD163
IL-12(p40)	IL-28A/IFN- λ 2	Chitinase-3- like1/YKL-40	Osteopontin	IL-6
IL-12(p70)	IL-27(p28)	gp130/sIL-6R β	sTNFR1	sIL-6R
IL17A	IFN- γ	IFN- α 2	sTNFR2	
IL-20	MMP-1	IFN- β	TSLP	
IL-22	Osteocalcin	sCD25/IL-R2	TWEAK/TNFSF12	
IL-26	VCAM-1	IL-8	Leptin	
	IL-19	Resistin		
	L-35	Adiponectin		
	LIGHT/TNFSF14			